281 related articles for article (PubMed ID: 28074487)
1. Higher 25-hydroxyvitamin D levels are associated with greater odds of remission with anti-tumour necrosis factor-α medications among patients with inflammatory bowel diseases.
Winter RW; Collins E; Cao B; Carrellas M; Crowell AM; Korzenik JR
Aliment Pharmacol Ther; 2017 Mar; 45(5):653-659. PubMed ID: 28074487
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment 25-hydroxyvitamin D levels and durability of anti-tumor necrosis factor-α therapy in inflammatory bowel diseases.
Zator ZA; Cantu SM; Konijeti GG; Nguyen DD; Sauk J; Yajnik V; Ananthakrishnan AN
JPEN J Parenter Enteral Nutr; 2014; 38(3):385-91. PubMed ID: 24088707
[TBL] [Abstract][Full Text] [Related]
3. The Relevance of Vitamin D and Antinuclear Antibodies in Patients with Inflammatory Bowel Disease Under Anti-TNF Treatment: A Prospective Study.
Santos-Antunes J; Nunes AC; Lopes S; Macedo G
Inflamm Bowel Dis; 2016 May; 22(5):1101-6. PubMed ID: 26818421
[TBL] [Abstract][Full Text] [Related]
4. Benefit of Earlier Anti-TNF Treatment on IBD Disease Complications?
Nuij V; Fuhler GM; Edel AJ; Ouwendijk RJ; Rijk MC; Beukers R; Quispel R; van Tilburg AJ; Tang TJ; Smalbraak H; Bruin KF; Lindenburg F; Peyrin-Biroulet L; van der Woude CJ;
J Crohns Colitis; 2015 Nov; 9(11):997-1003. PubMed ID: 26223842
[TBL] [Abstract][Full Text] [Related]
5. Optimal doses of methotrexate combined with anti-TNF therapy to maintain clinical remission in inflammatory bowel disease.
Colman RJ; Rubin DT
J Crohns Colitis; 2015 Apr; 9(4):312-7. PubMed ID: 25616487
[TBL] [Abstract][Full Text] [Related]
6. Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases.
Ungar B; Levy I; Yavne Y; Yavzori M; Picard O; Fudim E; Loebstein R; Chowers Y; Eliakim R; Kopylov U; Ben-Horin S
Clin Gastroenterol Hepatol; 2016 Apr; 14(4):550-557.e2. PubMed ID: 26538204
[TBL] [Abstract][Full Text] [Related]
7. The Impact of Vitamin D on Response to Anti-tumor Necrosis Factor-α Therapy in Children With Inflammatory Bowel Disease.
Hizarcioglu-Gulsen H; Kaplan JL; Moran CJ; Israel EJ; Lee H; Winter H
J Pediatr Gastroenterol Nutr; 2021 May; 72(5):e125-e131. PubMed ID: 33847289
[TBL] [Abstract][Full Text] [Related]
8. Outcome of inflammatory bowel disease patients treated with TNF-α inhibitors: two-year follow-up.
Lehtola E; Haapamäki J; Färkkilä MA
Scand J Gastroenterol; 2016 Dec; 51(12):1476-1481. PubMed ID: 27686143
[TBL] [Abstract][Full Text] [Related]
9. Association of polymorphisms in promoter region of TNF-α -238 and -308 with clinical outcomes in patients with immune-mediated inflammatory diseases on anti-TNF therapy.
Miler M; Nikolac Gabaj N; Ćelap I; Grazio S; Tomašić V; Bišćanin A; Mitrović J; Đerek L; Morović-Vergles J; Vrkić N; Štefanović M
Rheumatol Int; 2021 Dec; 41(12):2195-2203. PubMed ID: 34623480
[TBL] [Abstract][Full Text] [Related]
10. Safe and effective: anti-tumour necrosis factor therapy use in pregnant patients with Crohn disease and ulcerative colitis.
Kiely CJ; Subramaniam K; Platten J; Pavli P
Intern Med J; 2016 May; 46(5):616-9. PubMed ID: 27170239
[TBL] [Abstract][Full Text] [Related]
11. Factors Associated with Discontinuation of Anti-TNF Inhibitors Among Persons with IBD: A Population-Based Analysis.
Targownik LE; Tennakoon A; Leung S; Lix LM; Nugent Z; Singh H; Bernstein CN
Inflamm Bowel Dis; 2017 Mar; 23(3):409-420. PubMed ID: 28221250
[TBL] [Abstract][Full Text] [Related]
12. Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD).
Porcari S; Viola A; Orlando A; Privitera AC; Ferracane C; Cappello M; Vitello A; Siringo S; Inserra G; Magnano A; Mocciaro F; Di Mitri R; Belluardo N; Fidanza O; Garufi S; Magrì G; Bertolami C; Carroccio A; Macaluso FS; Renna S; Ventimiglia M; Alibrandi A; Cottone M; Fries W;
Drugs Aging; 2020 May; 37(5):383-392. PubMed ID: 32016824
[TBL] [Abstract][Full Text] [Related]
13. Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents.
Eickstaedt JB; Killpack L; Tung J; Davis D; Hand JL; Tollefson MM
Pediatr Dermatol; 2017 May; 34(3):253-260. PubMed ID: 28211161
[TBL] [Abstract][Full Text] [Related]
14. Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease.
Strik AS; van den Brink GR; Ponsioen C; Mathot R; Löwenberg M; D'Haens GR
Aliment Pharmacol Ther; 2017 Apr; 45(8):1128-1134. PubMed ID: 28230306
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B Virus Screening and Reactivation in a National VA Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Antagonists.
Shah R; Ho EY; Kramer JR; Richardson P; Sansgiry S; El-Serag HB; Hou JK
Dig Dis Sci; 2018 Jun; 63(6):1551-1557. PubMed ID: 29663266
[TBL] [Abstract][Full Text] [Related]
16. Distinct Association of Serum Vitamin D Concentration with Disease Activity and Trough Levels of Infliximab and Adalimumab during Inflammatory Bowel Disease Treatment.
Mechie NC; Mavropoulou E; Ellenrieder V; Kunsch S; Cameron S; Amanzada A
Digestion; 2020; 101(6):761-770. PubMed ID: 31536991
[TBL] [Abstract][Full Text] [Related]
17. Semen Quality and Sperm DNA Integrity in Patients With Severe Active Inflammatory Bowel Disease and Effects of Tumour Necrosis Factor-alpha Inhibitors.
Grosen A; Bungum M; Christensen LA; Cordelli E; Larsen OH; Leter G; Julsgaard M; Vestergaard T; Villani P; Hvas CL; Kelsen J
J Crohns Colitis; 2019 Apr; 13(5):564-571. PubMed ID: 30500868
[TBL] [Abstract][Full Text] [Related]
18. Antibody Response to Hepatitis B Virus Vaccine is Impaired in Patients With Inflammatory Bowel Disease on Infliximab Therapy.
Pratt PK; David N; Weber HC; Little FF; Kourkoumpetis T; Patts GJ; Weinberg J; Farraye FA
Inflamm Bowel Dis; 2018 Jan; 24(2):380-386. PubMed ID: 29361083
[TBL] [Abstract][Full Text] [Related]
19. The safety and efficacy of antitumour necrosis factor-alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series.
Sandhu A; Alameel T; Dale CH; Levstik M; Chande N
Aliment Pharmacol Ther; 2012 Jul; 36(2):159-65. PubMed ID: 22616981
[TBL] [Abstract][Full Text] [Related]
20. Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factor.
Ben-Horin S; Ungar B; Kopylov U; Lahat A; Yavzori M; Fudim E; Picard O; Peled Y; Eliakim R; Del Tedesco E; Paul S; Roblin X
Aliment Pharmacol Ther; 2018 Apr; 47(8):1117-1125. PubMed ID: 29446098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
